Company
SGX Catalist:1H3
Operates medical clinics and diagnostic services across Singapore, the Philippines and Hong Kong, including imaging, general health screening and vaccination. Its longevity relevance is limited and indirect: it is a clinic and screening operator, not a company developing ageing-biology interventions or aging-specific biomarker panels. The relevant exposure is preventive health screening infrastructure in Southeast Asia, which sits adjacent to the longevity clinic market. Financial condition is weak: FY2025 revenue of S$9.93m was flat year on year while net loss widened to S$12.91m, and the shares trade at S$0.001 on the SGX Catalist board with a market capitalisation of roughly S$6.4m. Include only with that caveat.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | SGX Catalist |
| Ticker | SGX Catalist:1H3 |
| Secondary listing | None |
| Market cap | Approximately S$6.4m (July 2026, stockanalysis.com; share price S$0.001, 6.44bn shares outstanding) |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
People
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
FY2025 results (year ended 31 December 2025, adopted at the AGM on 23 April 2026) showed revenue of S$9.93m, essentially flat year on year, with net loss widening to S$12.91m, roughly 258% worse than 2024. The company has since continued issuing shares at sub-cent prices, including an allotment of 2.1m shares at S$0.0018 in June 2026.
Keep reading
Sources
Every entity profile on variis is sourced. Not investment advice.